• By ICR Secretariat
  • Posted Friday, March 15, 2019

FDA approves J&J's esketamine as faster-acting depression treatment

https://www.biopharmadive.com/news/johnson-esketamine-approval-faster-acting-depression-drug/549848/

The Food and Drug Administration on Tuesday approved Johnson & Johnson's depression drug esketamine, clearing the first therapy in decades that works differently than existing treatments for the debilitating mood disorder.